ClearVitals — Remote Monitoring for Chronic Care at Home

Business Plan

Executive Summary

ClearVitals is a US-based healthtech company delivering cellular-connected remote patient monitoring (RPM) and chronic care management (CCM) services for patients with hypertension and diabetes. We ship plug-and-play blood-pressure cuffs and glucometers — no Wi-Fi configuration required — paired with a patient-facing mobile app and a nurse-led monitoring team embedded into primary care and specialty clinics.

Clinics bill Medicare and commercial payers under established CMS reimbursement codes (CPT 99453, 99454, 99457, 99458, 99490, 99491) and retain a meaningful portion of reimbursement, while ClearVitals earns a per-enrolled-patient, per-month SaaS and device fee. The model converts chronic disease management from a cost center into a new revenue line for practices.

The opportunity is large and immediate. ~37 million Americans have diagnosed diabetes; ~116 million have hypertension. RPM billing uptake among eligible Medicare beneficiaries remains below 5%, representing a significant greenfield. The US RPM market is projected to exceed $5 billion by 2027.

ClearVitals targets $1.2M ARR by end of Year 1, $6.8M by Year 2, and $22M by Year 3, driven by clinic partnerships across primary care, federally qualified health centers (FQHCs), and nephrology groups. Gross margins target 62% at scale.

We are seeking $4.5M in Seed funding to hire a clinical operations team, complete HIPAA-compliant infrastructure hardening, expand device logistics, and sign 30 clinic partners in three anchor markets: Dallas, Chicago, and Atlanta.

> ClearVitals sits at the intersection of a proven reimbursement mechanism, an underserved patient population, and a distribution channel — clinics — that is actively motivated to adopt because it generates net-positive revenue per enrolled patient.

---

Company Description

Legal name: ClearVitals, Inc. (Delaware C-Corp) Founded: 2024 Headquarters: Austin, TX (operations hub; field teams in Dallas, Chicago, Atlanta)

ClearVitals was founded on the observation that clinics already own the patient relationships needed to scale chronic disease monitoring — they simply lack the infrastructure, staffing, and billing expertise to operationalize RPM and CCM programs profitably. ClearVitals provides all three.

Our core offering bundles: FDA-cleared, cellular-enabled biometric devices (blood-pressure cuffs; glucometers) A HIPAA-compliant patient app (iOS and Android) with plain-language health summaries A nurse-led monitoring team that reviews data daily, manages escalations, and documents clinical interactions to support billing A clinic-facing dashboard for providers with real-time patient data, alert management, and automated billing-ready reports

ClearVitals operates as a B2B2C company: the clinic is the customer; the patient is the end user. This concentrates sales effort on a reachable, financially motivated buyer while benefiting tens of thousands of patients at home.

Mission: Make continuous, nurse-supported chronic disease management the standard of care for every American managing hypertension or diabetes at home.

Current status: Pre-revenue, seed stage. Pilot agreements under negotiation with two Dallas-area primary care groups (~180 eligible patients combined). MVP device firmware and app in closed beta. HIPAA Business Associate Agreement (BAA) template reviewed by healthcare counsel.

Regulatory posture: We act as a service provider under HIPAA (Business Associate), not a covered entity. Devices carry existing FDA 510(k) clearances from manufacturing partners. ClearVitals does not manufacture devices; it procures, kits, and ships them under contract with two device OEMs.

---

Problem & Customer

The clinical problem is measurable. Uncontrolled hypertension costs the US healthcare system an estimated $131 billion annually in downstream cardiovascular events. Type 2 diabetes accounts for ~$327 billion in direct and indirect costs per year. Both conditions are manageab